Zentalis®Pharmaceuticals, Inc. announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis? long-term portfolio strategy.

Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway. Prior to joining Zentalis, Ms. Freeman was Vice President, US Head of DDR Franchise, Oncology at AstraZeneca. She was responsible for overseeing the strategic direction and cross-functional efforts for LYNPARZA® (olaparib) and other therapies targeting the DDR pathway, which is an important hallmark in ovarian and other cancers.

Previously, she held various leadership roles at biopharmaceutical companies including Adaptimmune, Boehringer Ingelheim and GlaxoSmithKline. Ms. Freeman has also served on the Alliance for Regenerative Medicine (ARM) Cell Therapy Advisory Committee and has been recognized by Women in Bio as a Female Pioneer in the Life Sciences. After receiving her Bachelor of Science in Biology from Cornell University, Ms. Freeman was a Research Scientist in the Department of Hematology/Medical Oncology at Weill Cornell Medical Center and later pursued Graduate Studies at SUNY Upstate Medical Center.

Ms. Freeman also received Finance and Marketing Certificates from the Wharton School of the University of Pennsylvania.